Therapure Biopharma

Mississauga, Canada Founded: 2008 • Age: 18 yrs
Complex biologics are developed and manufactured by Therapure Biopharma.

About Therapure Biopharma

Therapure Biopharma is a Healthcare company based in Mississauga (Canada) founded in 2008. Complex biologics are developed and manufactured by Therapure Biopharma. Therapure Biopharma offers products and services including Biomanufacturing Services and Drug Innovations. Its focus areas include Diversified Pharmaceuticals, Biopharma Outsourcing, CDMO and Biologics. Its legal entity is Therapure Biopharma Inc.

Company details

Therapure Biopharma focuses on manufacturing complex biologics and on developing, manufacturing, and selling its blood and plasma-related therapeutic products. It operates through three divisions: Therapure Biomanufacturing (Mammalian cell line based CDMO), Therapure Biologics (Plasma-derived products), and Therapure Innovations (Proprietary drug development). It provides contract development and manufacturing services for integrated biologics and also offers drug discovery, research, and development services. The company also focuses on the development of a portfolio of its own plasma-derived protein therapeutics through its technology, PlasmaCap EBA (for efficient capture of plasma proteins at high yields and purities). Therapure Innovations lead candidates TBI 302 (liver cancer) and TBI 304H (anemia) are undergoing phase I trials while TBI 301 (Hep C) is in the discovery stage. The company is funded by the Catalyst Capital Group since its inception. The companys CDMO business and certain rights to their plasma products and technology for the Chinese market were acquired by a JV between 3SBio and CPE funds.

  • Headquarters Mississauga, Canada
  • Sectors
    Healthcare
  • Website therapurebio.com
  • Social LinkedIn X
  • Legal Name Therapure Biopharma Inc.
Key Metrics
  • Latest Funding Round
    $20M (USD), Debt – Conventional

    Aug 2015

  • Investors

Products & Services of Therapure Biopharma

Therapure Biopharma offers a comprehensive portfolio of products and services, including Biomanufacturing Services and Drug Innovations.

Biomanufacturing Services
Contract Manufacturing

Offers integrated biologics CDMO for efficient production and development.

Drug Innovations
Research and Development

Develops protein therapeutics for diseases like liver cancer and anemia.

Funding Insights of Therapure Biopharma

  • Total Rounds 2
  • Last Round Debt – Conventional — $20M
  • First Round $4.2M

    (Apr 2010)

  • Investors Count 2

All 2 funding rounds of Therapure Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2015$20MDebt – Conventional––
Apr 2010$4.2MGrant––
Valuation history

2 investors in total: 2 institutional.

Investors in Therapure Biopharma

Therapure Biopharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Ontario Canada and FedDev Ontario.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
It serves as a government backed investment fund focused on the economic growth of southern ontorio.
2009feddevontario.gc.caWaterloo, Canada
Access government services and products
1881ontario.caToronto, Canada
Premium access

Investor details for Therapure Biopharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Therapure Biopharma

3 dated milestones of Therapure Biopharma across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Therapure Biopharma is founded.
  2. Funding First funding round of $4.2M.
  3. Funding Latest funding round, Debt – Conventional, of $20.0M.

Web traffic of Therapure Biopharma

Websites that share an audience with Therapure Biopharma (therapurebio.com).

Similar websites

Websites whose visitors overlap most with Therapure Biopharma. Affinity shows how closely the audiences match.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Therapure Biopharma

Premium access

Complete news archive for Therapure Biopharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Therapure Biopharma

Therapure Biopharma was founded in 2008 and raised its 1st funding round 2 years after it was founded.

Therapure Biopharma is headquartered in Mississauga, Canada. It is registered at Mississauga, Ontario, Canada.

Therapure Biopharma focuses on manufacturing complex biologics and on developing, manufacturing, and selling its blood and plasma-related therapeutic products. It operates through three divisions: Therapure Biomanufacturing (Mammalian cell line based CDMO), Therapure Biologics (Plasma-derived products), and Therapure Innovations (Proprietary drug development). It provides contract development and manufacturing services for integrated biologics and also offers drug discovery, research, and development services. The company also focuses on the development of a portfolio of its own plasma-derived protein therapeutics through its technology, PlasmaCap EBA (for efficient capture of plasma proteins at high yields and purities). Therapure Innovations lead candidates TBI 302 (liver cancer) and TBI 304H (anemia) are undergoing phase I trials while TBI 301 (Hep C) is in the discovery stage. The company is funded by the Catalyst Capital Group since its inception. The companys CDMO business and certain rights to their plasma products and technology for the Chinese market were acquired by a JV between 3SBio and CPE funds.

Therapure Biopharma offers Biomanufacturing Services and Drug Innovations.

Therapure Biopharma has 2 investors. Key investors include Ontario Canada, and FedDev Ontario.

Therapure Biopharma operates through Therapure Biopharma Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available